---
reference_id: "PMID:39438660"
title: A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease.
authors:
- Thomas T
- Friedrich M
- Rich-Griffin C
- Pohin M
- Agarwal D
- Pakpoor J
- Lee C
- Tandon R
- Rendek A
- Aschenbrenner D
- Jainarayanan A
- Voda A
- Siu JHY
- Sanches-Peres R
- Nee E
- Sathananthan D
- Kotliar D
- Todd P
- Kiourlappou M
- Gartner L
- Ilott N
- Issa F
- Hester J
- Turner J
- Nayar S
- Mackerodt J
- Zhang F
- Jonsson A
- Brenner M
- Raychaudhuri S
- Kulicke R
- Ramsdell D
- Stransky N
- Pagliarini R
- Bielecki P
- Spies N
- Marsden B
- Taylor S
- Wagner A
- Klenerman P
- Walsh A
- Coles M
- Jostins-Dean L
- Powrie FM
- Filer A
- Travis S
- Uhlig HH
- Dendrou CA
- Buckley CD
journal: Nat Immunol
year: '2024'
doi: 10.1038/s41590-024-01994-8
content_type: abstract_only
---

# A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease.
**Authors:** Thomas T, Friedrich M, Rich-Griffin C, Pohin M, Agarwal D, Pakpoor J, Lee C, Tandon R, Rendek A, Aschenbrenner D, Jainarayanan A, Voda A, Siu JHY, Sanches-Peres R, Nee E, Sathananthan D, Kotliar D, Todd P, Kiourlappou M, Gartner L, Ilott N, Issa F, Hester J, Turner J, Nayar S, Mackerodt J, Zhang F, Jonsson A, Brenner M, Raychaudhuri S, Kulicke R, Ramsdell D, Stransky N, Pagliarini R, Bielecki P, Spies N, Marsden B, Taylor S, Wagner A, Klenerman P, Walsh A, Coles M, Jostins-Dean L, Powrie FM, Filer A, Travis S, Uhlig HH, Dendrou CA, Buckley CD
**Journal:** Nat Immunol (2024)
**DOI:** [10.1038/s41590-024-01994-8](https://doi.org/10.1038/s41590-024-01994-8)

## Content

1. Nat Immunol. 2024 Nov;25(11):2152-2165. doi: 10.1038/s41590-024-01994-8. Epub 
2024 Oct 22.

A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in 
inflammatory bowel disease.

Thomas T(1)(2)(3), Friedrich M(#)(1)(3), Rich-Griffin C(#)(2), Pohin M(#)(1), 
Agarwal D(#)(1), Pakpoor J(1)(2)(3), Lee C(1), Tandon R(4), Rendek A(5), 
Aschenbrenner D(3), Jainarayanan A(1), Voda A(1), Siu JHY(1), Sanches-Peres 
R(1), Nee E(1), Sathananthan D(6)(7), Kotliar D(8)(9), Todd P(2), Kiourlappou 
M(2), Gartner L(3), Ilott N(1), Issa F(10), Hester J(10), Turner J(11), Nayar 
S(11)(12)(13), Mackerodt J(1), Zhang F(8)(9)(14), Jonsson A(8)(9), Brenner 
M(8)(9), Raychaudhuri S(8)(9), Kulicke R(15), Ramsdell D(15), Stransky N(15), 
Pagliarini R(15), Bielecki P(15), Spies N(15), Marsden B(2), Taylor S(2), Wagner 
A(16)(17), Klenerman P(3), Walsh A(3), Coles M(1), Jostins-Dean L(1), Powrie 
FM(1), Filer A(11)(12)(13), Travis S(18)(19)(20), Uhlig HH(21)(22)(23), Dendrou 
CA(24)(25)(26), Buckley CD(27)(28)(29)(30).

Author information:
(1)Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
(2)Centre for Human Genetics, University of Oxford, Oxford, UK.
(3)Translational Gastroenterology & Liver Unit, John Radcliffe Hospital, 
Headington, Oxford, UK.
(4)University College London Hospitals NHS Foundation Trust, London, UK.
(5)Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
(6)University of Adelaide, Adelaide, Australia.
(7)Lyell McEwin Hospital, Adelaide, Australia.
(8)Broad Institute of MIT and Harvard, Cambridge, MA, USA.
(9)Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
(10)Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
(11)Rheumatology Research Group, Institute of Inflammation and Ageing, 
University of Birmingham, Birmingham, UK.
(12)National Institute for Health Research (NIHR) Birmingham Biomedical Research 
Centre and NIHR Clinical Research Facility, University Hospitals Birmingham NHS 
Foundation Trust, Birmingham, UK.
(13)Birmingham Tissue Analytics, Institute of Translational Medicine, University 
of Birmingham, Birmingham, UK.
(14)Center for Health AI, University of Colorado Anschutz, Anschutz, CO, USA.
(15)Celsius Therapeutics, Cambridge, MA, USA.
(16)Department of Electrical Engineering and Computer Science, University of 
California, Berkeley, Berkeley, CA, USA.
(17)The Center for Computational Biology, University of California, Berkeley, 
Berkeley, CA, USA.
(18)Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. 
simon.travis@kennedy.ox.ac.uk.
(19)Translational Gastroenterology & Liver Unit, John Radcliffe Hospital, 
Headington, Oxford, UK. simon.travis@kennedy.ox.ac.uk.
(20)NIHR Oxford Biomedical Research Centre, Oxford, UK. 
simon.travis@kennedy.ox.ac.uk.
(21)Translational Gastroenterology & Liver Unit, John Radcliffe Hospital, 
Headington, Oxford, UK. holm.uhlig@ndm.ox.ac.uk.
(22)NIHR Oxford Biomedical Research Centre, Oxford, UK. holm.uhlig@ndm.ox.ac.uk.
(23)Department of Paediatrics, University of Oxford, Oxford, UK. 
holm.uhlig@ndm.ox.ac.uk.
(24)Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. 
calliope.dendrou@kennedy.ox.ac.uk.
(25)Centre for Human Genetics, University of Oxford, Oxford, UK. 
calliope.dendrou@kennedy.ox.ac.uk.
(26)NIHR Oxford Biomedical Research Centre, Oxford, UK. 
calliope.dendrou@kennedy.ox.ac.uk.
(27)Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. 
christopher.buckley@kennedy.ox.ac.uk.
(28)Translational Gastroenterology & Liver Unit, John Radcliffe Hospital, 
Headington, Oxford, UK. christopher.buckley@kennedy.ox.ac.uk.
(29)Rheumatology Research Group, Institute of Inflammation and Ageing, 
University of Birmingham, Birmingham, UK. christopher.buckley@kennedy.ox.ac.uk.
(30)NIHR Oxford Biomedical Research Centre, Oxford, UK. 
christopher.buckley@kennedy.ox.ac.uk.
(#)Contributed equally

Precision medicine in immune-mediated inflammatory diseases (IMIDs) requires a 
cellular understanding of treatment response. We describe a therapeutic atlas 
for Crohn's disease (CD) and ulcerative colitis (UC) following adalimumab, an 
anti-tumour necrosis factor (anti-TNF) treatment. We generated ~1 million 
single-cell transcriptomes, organised into 109 cell states, from 216 gut 
biopsies (41 subjects), revealing disease-specific differences. A systems 
biology-spatial analysis identified granuloma signatures in CD and interferon 
(IFN)-response signatures localising to T cell aggregates and epithelial damage 
in CD and UC. Pretreatment differences in epithelial and myeloid compartments 
were associated with remission outcomes in both diseases. Longitudinal 
comparisons demonstrated disease progression in nonremission: myeloid and T cell 
perturbations in CD and increased multi-cellular IFN signalling in UC. IFN 
signalling was also observed in rheumatoid arthritis (RA) synovium with a 
lymphoid pathotype. Our therapeutic atlas represents the largest cellular census 
of perturbation with the most common biologic treatment, anti-TNF, across 
multiple inflammatory diseases.

© 2024. The Author(s).

DOI: 10.1038/s41590-024-01994-8
PMCID: PMC11519010
PMID: 39438660 [Indexed for MEDLINE]

Conflict of interest statement: T.T. has received research support from Celsius 
Therapeutics and consulting fees from Abbvie and ZuraBio. D.A. is an employee 
and shareholder of Novartis Pharma AG. This article reflects the authors’ 
personal opinions and not that of their employer. R.P. is employed by Scorpion 
Therapeutics and holds equity in Celsius Therapeutics. F.M.P. received research 
support from Roche and Janssen and consulting fees from GSK, Novartis and 
Genentech. H.H.U. received research support or consultancy fees from Janssen, 
Eli Lilly, UCB Pharma, BMS/Celgene, MiroBio, Mestag and OMass. A.F. has 
consulted for Janssen and Sonoma and has received research funding from BMS, 
Roche, UCB, Nascient, Mestag, GSK and Janssen. S.T. has received grants and 
research support from AbbVie, Buhlmann, Celgene, Celsius, ECCO, Helmsley Trust, 
IOIBD, Janssen, Lilly, Pfizer, Takeda, UKIERI, Vifor and Norman Collisson 
Foundation; consulting fees from AbbVie, ai4gi, Allergan, Amgen, Apexian, 
Arcturis, Arena, AstraZeneca, Bioclinica, Biogen, BMS, Buhlmann, Celgene, 
ChemoCentryx, Clario, Cosmo, Dynavax, Endpoint Health, Enterome, EQrX, 
Equillium, Ferring, Galapagos, Genentech/Roche, Gilead, GSK, Immunocore, Indigo, 
Janssen, Lilly, Mestag, Microbiotica, Novartis, Pfizer, Phesi, Protagonist, 
Sanofi, Satisfai, Sensyne Health, Sorriso, Syndermix, Takeda, Theravance, 
Topivert, UCB Pharma, VHsquared and Vifor; and speaker fees from AbbVie, Amgen, 
Biogen, BMS, Falk, Ferring, Janssen, Lilly, Pfizer and Takeda. C.D.B., M.B., 
M.C. and S.R. are founders of Mestag Therapeutics. M.F. received research 
support and consulting fees from Eli Lilly and Ono Pharmaceuticals. The 
remaining authors declare no competing interests.